Drug Profile
MGB BP 3
Alternative Names: MGB-BP-3Latest Information Update: 15 Jun 2022
Price :
$50
*
At a glance
- Originator MGB Biopharma; University of Strathclyde
- Developer MGB Biopharma
- Class Anti-infectives; Antibacterials; DNA-binding proteins; Small molecules
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Clostridium difficile infections
- Preclinical Gram-positive infections; Skin and soft tissue infections
Most Recent Events
- 14 Jun 2022 MGB BP 3 is still in preclinical trials for skin and soft tissue infections in the United Kingdom (MGB Biopharma pipeline, June 2022)
- 27 Jan 2021 MGB Biopharma announces intention to submit NDA to the USFDA for Clostridioides difficile Infections in USA
- 27 Jan 2021 MGB Biopharma plans two phase III trials for Clostridium difficile infections in USA